Incyte is 'optimistic' about skin disease drug Opzelura as prescriptions grow 77% in Q4
Incyte expects its atopic dermatitis and vitiligo treatment Opzelura to be a “key contributor” to growth in 2024 after sales jumped 78% in the fourth …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
